Lipid abnormalities in kidney disease and management strategies

doi:10.5527/wjn.v4.i1.83

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 1

This Article

(416)

(330)

(0)

(7668)

(48)

Peer-Review Report of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Nephrology

ISSN

2220-6124

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Minireviews

World J Nephrol. Feb 6, 2015; 4(1): 83-91
Published online Feb 6, 2015. doi: 10.5527/wjn.v4.i1.83

Table 3 Kidney diseases: improving global outcomes recommended doses of commonly used statins, based on doses used in trials, in patients with estimated glomerular filtration rate < 60[9,35,45-47]

	Dose (mg/d)
Fluvastatin	80
Atorvastatin	20
Rosuvastatin	10
Simvastatin/ezetimibe	20/10
Pravastatin	40
Simvastatin	40
Pitavastatin	2

Full Size Table

Citation: Pandya V, Rao A, Chaudhary K. Lipid abnormalities in kidney disease and management strategies. World J Nephrol 2015; 4(1): 83-91
URL: https://www.wjgnet.com/2220-6124/full/v4/i1/83.htm
DOI: https://dx.doi.org/10.5527/wjn.v4.i1.83

Pandya V, Rao A, Chaudhary K. Lipid abnormalities in kidney disease and management strategies. World J Nephrol 2015; 4(1): 83-91 [PMID: 25664249 DOI: 10.5527/wjn.v4.i1.83]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.